Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

This article was originally published on Nasdaq

Radius Health, Inc. RDUS and partner The Menarini Group recently announced that the latter has submitted a new drug application (NDA) to the FDA for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.

Responses